A Novel Method to Identify Antigens Which Act Co-Operatively To Treat Established Tumors Using Viral-Expressed cDNA Libraries

Technology #2012-049

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Richard G. Vile Ph.D.
Jill M. Thompson
Jose S. Pulido M.D., M.S., M.B.A.
Timothy J. Kottke
Managed By
Panya Taysavang
Patent Protection
US Patent Pending
US Patent Pending
US Patent Pending
US Patent Pending
US Patent Pending
US Patent Pending

We describe a novel technology to define new repertoires of tumor antigen(s) which work alone or in combination to generate anti tumor immune responses. Definition of arrays of antigens which co-operate in vivo to cure established tumors will inform future strategies for novel clinical vaccines through the use of vesicular stomatis virus with cDNA libraries constructed with selected, relevant and defined epitopes which can be readily manufactured for clinical use. This technology will be directly applicable to the treatment of a broad range of different cancer types as well as to antigen discovery in diseases where pathology is induced by immune reactivity against a single or multiple target antigens. We have previously shown that a VSV-cDNA library encoding the organ specific or tumor specific (xeno or auto) tissue could be used as a vaccine. VSV-cDNA libraries were generated as described previously by us. We developed an in vitro screen based upon the ability of LN/splenocytes from treated mice to present tumor associated epitopes from the VSV-cDNA library upon in vitro infection/stimulation to memory IL-17 CD4+ T cells which then secreted IL-17 in response to melanoma, but not prostate, tumor cell lysates.